People · Operator
Named in public records as an officer, director or promoter · active 2015–2020 · Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tallac Therapeutics, Inc. | — | Pharma | Series C | $61.6M | $2.2B | 2020 |
| Alexo Therapeutics Ltd | — | Biotechnology | Series B | $18.0M | $715.3M | 2015 |
Jaume Pons at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jaume Pons on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Corey Goodman | 2 | 13 |
| Isaac Cheng | 1 | 9 |
| Michael Carusi | 1 | 7 |
| Christine Brennan | 1 | 3 |
| Jason Lettman | 1 | 2 |
| Ran Geng | 1 | 1 |
| Hong Wan | 1 | 1 |
| N/a Bradwell Limited | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.